{"id":114804,"date":"2021-06-02T15:51:11","date_gmt":"2021-06-02T22:51:11","guid":{"rendered":"http:\/\/www.lankaweb.com\/news\/items\/?p=114804"},"modified":"2021-06-02T15:51:11","modified_gmt":"2021-06-02T22:51:11","slug":"sputnik-v","status":"publish","type":"post","link":"https:\/\/www.lankaweb.com\/news\/items\/2021\/06\/02\/sputnik-v\/","title":{"rendered":"Sputnik V"},"content":{"rendered":"

Sputnik V Vaccine<\/em><\/span><\/h2>\n\n\n

GENERAL INFORMATION<\/h4>\n\n\n\n

Sputnik V is the world\u2019s first registered vaccine based on a well-studied human adenoviral vector-based platform. Sputnik V is already registered in more than 65 countries.<\/p>\n\n\n\n

The ongoing Sputnik V post-registration clinical trial in Russia involved more than 31,000 volunteers. Phase 3 clinical trials of Sputnik V have been conducting in the UAE, India, Venezuela and Belarus.<\/p>\n\n\n\n

Sputnik V is one of the three vaccines in the world with efficacy of over 90%. The Vaccine\u2019s efficacy is confirmed at 91.6% based on the analysis of data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.<\/p>\n\n\n\n

According to analysis of data from 3.8 million vaccinated persons in Russia Sputnik V demonstrates 97.6% efficacy.<\/p>\n\n\n\n

RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The cost of one dose of the vaccine for international markets is less than $10 (Sputnik V is a two dose vaccine). The vaccine can be stored at a temperature of +2 to +8 degrees Celsius, which allows for easy distribution worldwide, including hard-to-reach regions.<\/p>\n\n\n\n

The vaccine supplies for the global market will be produced by RDIF\u2019s international partners in India, Brazil, China, South Korea and other countries.<\/p>\n\n\n\n

This website has been created to provide accurate and up-to-date information about Sputnik V.<\/p>\n\n\n\n

Russian Health Ministry registration certificate<\/a><\/p>\n\n\n\n

The vaccine is named after the first Soviet space satellite. The launch of Sputnik-1 in 1957 reinvigorated space research around the world, creating a so called Sputnik moment\u201d<\/a> for the global community.<\/p>\n\n\n\n

The Russian Ministry of Health, the Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF, Russia\u2019s sovereign wealth fund) announce that Sputnik Light, a single dose COVID-19 vaccine, has received authorization for use in Russia.<\/p>\n\n\n\n

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V \u2013 the world\u2019s first registered vaccine against coronavirus.<\/p>\n\n\n\n

The single dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered as part of Russia\u2019s mass vaccination program between 5 December 2020 and 15 April 2021.<\/p>\n\n\n\n

An efficacy level of almost 80% is higher than that of many two-dose vaccines.<\/p>\n\n\n\n

Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.<\/p>\n\n\n\n

Phase I\/II of the Safety and Immunogenicity Study of the Sputnik Light vaccine has demonstrated that:<\/p>\n\n\n\n